HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

WBA lifted by Rite Aid

This article was originally published in OTC Bulletin & The Rose Sheet

Executive Summary

Acquiring a group of Rite Aid stores at the end of 2018 helped Walgreens Boots Alliance (WBA) post a 12.1% rise in sales to US$33.0 billion (€26.7 billion) in its second quarter ended 28 February 2018. At constant currencies, sales advanced by 9.4%.

Acquiring a group of Rite Aid stores at the end of 2018 helped Walgreens Boots Alliance (WBA) post a 12.1% rise in sales to US$33.0 billion (€26.7 billion) in its second quarter ended 28 February 2018. At constant currencies, sales advanced by 9.4%.

Having acquired 357 Rite Aid stores as of 31 December 2017, turnover at WBA’s Retail Pharmacy USA division advanced by 12.2% to US$24.5 billion in the quarter. Prescription sales, which accounted for 70.3% of the total, had increased by 18.7%, WBA noted, while prescription sales in comparable stores had improved by 5.1%.

WBA secured regulatory approval to acquire less than half of Rite Aid’s 4,624 stores, after amending the deal for a third time to satisfy competition concerns (OTC bulletin, 6 October 2017, page 7).

The revised US$4.38 billion agreement will see the wholesale and retail giant acquire 1,932 Rite Aid stores – located primarily in the North-Eastern and Southern US – along with three distribution centres and related inventory.

Once the deal closes in spring 2018, WBA will launch a US$450 million store optimisation programme in the country (OTC bulletin, 3 November 2017, page 8).

As part of this programme, the firm said it expected to close “approximately 600 stores”.

By late 2020, WBA expects to spend around US$750 million in integrating the acquired Rite Aid drugstores, three distribution centres and related assets. Another US$500 million of capital expenditure will be devoted to store conversions, offset by more than US$300 million in anticipated annual synergies “derived primarily from procurement, cost savings and other operational matters”.

Outside the US, WBA reported turnover at its Retail Pharmacy International business – consisting of health and beauty chains in eight countries, the largest of which is Boots UK – up by 7.0% to US$3.3 billion in the three months, thanks entirely to positive currency effects. At constant currencies, sales actually declined by 2.6%.

WBA’s global Pharmaceutical Wholesale business – which mainly operates under the Alliance Healthcare brand – reported second-quarter sales up by 14.4% to US$5.8 billion. At constant currencies, the rise was a more modest 3.4%.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS122107

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel